T-cell Lymphomas Clinical Trials

7 recruitingLast updated: June 20, 2026

There are 7 actively recruiting t-cell lymphomas clinical trials across 4 countries. Studies span Phase 2, Phase 1. Top locations include New York, New York, United States, Basking Ridge, New Jersey, United States, Beijing, Beijing Municipality, China. Updated daily from ClinicalTrials.gov.


T-cell Lymphomas Trials at a Glance

7 actively recruiting trials for t-cell lymphomas are listed on ClinicalTrialsFinder across 6 cities in 4 countries. The largest study group is Phase 2 with 5 trials, with the heaviest enrollment activity in New York, Basking Ridge, and Beijing. Lead sponsors running t-cell lymphomas studies include Dizal Pharmaceuticals, Fondazione IRCCS Policlinico San Matteo di Pavia, and Bristol-Myers Squibb.

Browse t-cell lymphomas trials by phase

Treatments under study

About T-cell Lymphomas Clinical Trials

Looking for clinical trials for T-cell Lymphomas? There are currently 2 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new T-cell Lymphomas trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about T-cell Lymphomas clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 17 of 7 trials

Recruiting
Phase 2

Allogeneic Hematopoietic Cell Transplantation for Peripheral T Cell Lymphoma

Lymphoproliferative DisordersImmune System DiseasesPeripheral T-cell Lymphomas
National Cancer Institute (NCI)330 enrolled2 locationsNCT03922724
Recruiting
Phase 1Phase 2

Assessing Treatment of T-Cell Lymphoma With GW5282 in Combination With Golidocitinib (BEI-DOU3)

T-cell Lymphomas
Dizal Pharmaceuticals165 enrolled12 locationsNCT07496229
Recruiting
Phase 1

A Study of Ruxolitinib and Duvelisib in People With Lymphoma

T-cell Prolymphocytic LeukemiaT-cell LymphomasNK-Cell Lymphomas+1 more
Memorial Sloan Kettering Cancer Center70 enrolled9 locationsNCT05010005
Recruiting
Phase 2

Amping up With PemJAK

Non-Hodgkin LymphomaPeripheral T Cell LymphomaPrimary Mediastinal B Cell Lymphoma+5 more
Seda S. Tolu53 enrolled1 locationNCT07283822
Recruiting

Local Registry of Primary Cutaneous T-cell Lymphomas

Primary Cutaneous T-cell Lymphomas NCT Number
Fondazione IRCCS Policlinico San Matteo di Pavia600 enrolled1 locationNCT07160023
Recruiting
Phase 1Phase 2

A Study to Assess the Safety, Tolerability, Efficacy, and Drug Levels of BMS-986369 (Golcadomide) in Participants With Relapsed or Refractory T-cell Lymphomas in Japan (GOLSEEK-3)

Relapsed or Refractory T-cell Lymphomas
Bristol-Myers Squibb85 enrolled40 locationsNCT06035497
Recruiting
Phase 1Phase 2

Azacytidine Plus CAOLD Regimen in Relapsed/Refractory Peripheral T-Cell Lymphomas

Relapsed Peripheral T-Cell LymphomasRefractory Peripheral T-Cell Lymphomas
Navy General Hospital, Beijing52 enrolled1 locationNCT06176027